Association study between herpes zoster reporting and mRNA COVID‐19 vaccines (BNT162b2 and mRNA‐1273). Issue 7 (28th February 2022)

• Record Type: Journal Article
• Authors: Préta, Laure‐Hélène; Contejean, Adrien; Salvo, Francesco; Treluyer, Jean‐Marc; Charlier, Caroline; Chouchana, Laurent
• Is Part Of: British journal of clinical pharmacology. Volume 88:Issue 7(2022)
• Page Start: 3529
• Page End: 3534
• Publication Date: 2022-02-28
• Subjects: COVID‐19 -- disproportionality -- herpes zoster -- mRNA vaccines -- pharmacovigilance; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.15280
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Several cases of herpes zoster (HZ) following mRNA COVID‐19 vaccination (BNT162b2 and mRNA‐1273) have been reported, and the first epidemiological evidence suggests an increased risk. We used the worldwide pharmacovigilance database VigiBase to describe HZ cases following mRNA COVID‐19 vaccination. We performed disproportionality analyses (case/non‐case statistical approach) to assess the relative risk of HZ reporting in mRNA COVID‐19 vaccine recipients compared to influenza vaccine recipients and according to patient age. To 30 June 2021, of 716 928 reports with mRNA COVID‐19 vaccines, we found 7728 HZ cases. When compared to influenza vaccines, mRNA COVID‐19 vaccines were associated with a significantly higher reporting of HZ (reporting odds ratio 1.9, 95% CI 1.8–2.1). Furthermore, we found a reduced risk of reporting HZ among under 40‐year‐old persons compared to older persons (reporting odds ratio 0.39, 95% CI 0.36–0.41). Mild and infrequent HZ reactions may occur shortly after mRNA COVID‐19 vaccination, at higher frequency than reported with influenza vaccination, especially in patients over 40 years old. Further analyses are needed to confirm this risk.